Actigraphic assessment of sleep quality in the A4 trial

A4 试验中睡眠质量的活动记录评估

基本信息

批准号：
9108796
负责人：
PAUL B ROSENBERG
金额：
$ 33.72万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-15 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9108796
关键词：
Abeta clearance Accelerometer Active Immunization Address Affect Aging Aging-Related Process Alzheimer&apos s Disease Amyloid Amyloid deposition Area Beds Brain Cerebrospinal Fluid Circadian Rhythms Clinical Communities Complement Consent Data Deposition Drosophila melanogaster Elderly Enrollment Etiology Exhibits Health Human Individual Intravenous infusion procedures Measures Memory Disorders Methods Modeling Mus Observational Study Outcome Parents Participant Pathology Patient Self-Report Patients Persons Pittsburgh Compound-B Placebos Positron-Emission Tomography Prevention Prevention therapy Prevention trial Proxy Public Health Quality of life Randomized Randomized Controlled Trials Recruitment Activity Reporting Research Rest Risk Sampling Scanning Senile Plaques Sleep Sleep Fragmentations Sleep disturbances Therapeutic Intervention Time Wrist abeta accumulation abeta deposition actigraphy awake cost follow-up functional decline human very old age (85+)improved mouse model potential biomarker pre-clinical sleep onset therapy development

项目摘要

DESCRIPTION (provided by applicant): The Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) parent trial is a trial of anti-amyloid therapy for prevention of cognitiv decline in 1000 participants who are cognitively healthy, 65-85 years old, and have evidence of amyloid in their brain on flobetapir PET scans. Quality of sleep is important for quality of life ad there is evidence for poorer sleep quality in older persons and in persons at risk of developing Alzheimer's disease. Actigraphy is a low-cost noninvasive method of measuring activity validated for assessing sleep quality, using an accelerometer that is worn like a wristwatch. We propose to add actigraphic assessment of sleep quality in 50 amyloid-positive and 50 amyloid-negative participants who have consented to A4. We hope to assess the effect of anti-amyloid therapy on sleep quality, and the effect of baseline amyloid status on changes in sleep in the placebo and amyloid-negative group.

描述（由适用提供）：不对称阿尔茨海默氏病的抗淀粉样蛋白治疗（A4）父母试验是一项针对预防认知健康的抗淀粉样疗法的试验，以预防认知健康，65-85岁的参与者，并且有35-85岁的疗程，并且有疗程的证据表明，在Flobatapir Pet scans中有疗程。睡眠质量对于生活质量很重要，有证据表明，老年人和有患阿尔茨海默氏病风险的人的睡眠质量较差。 Actiography是一种低成本的无创方法，用于测量用于评估睡眠质量的活性，使用像手表一样穿着的加速度计。我们建议在50个淀粉样蛋白阳性和50名同意A4的淀粉样蛋白阴性参与者中对睡眠质量进行行程评估。我们希望评估抗淀粉样蛋白对睡眠质量的影响，以及基线淀粉样蛋白状况对安慰剂和淀粉样蛋白阴性组的睡眠变化的影响。